Fund Details
Overview
Investment portfolio
16rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Mentari Therapeutics | Jul 2026Participated | $200 MOther Equity | |
Mentari Therapeutics | May 2026Led | $290 MOther Equity | |
Korsana Biosciences | Feb 2026Participated | $150 MSeries A | |
Mirador Therapeutics | Jan 2026Participated | $250 MSeries B | |
Jade Biosciences | Oct 2024Participated | $95 MOther Equity | |
Candid Therapeutics | Sep 2024Led | $370 MOther Equity | |
Jade Biosciences | Aug 2024Led | $80 MOther Equity | |
Bicycle Therapeutics | May 2024Participated | $555 MOther Equity | |
Zenas BioPharma | May 2024Participated | $200 MSeries C | |
Mirador Therapeutics | Mar 2024Participated | $400 MOther Equity | |
Bicara Therapeutics | Dec 2023Participated | $165 MSeries C | |
Zenas BioPharma | Nov 2022Participated | $118 MSeries B | |
Mentari Therapeutics | Jul 2026Participated | $200 MOther Equity | |
Mentari Therapeutics | May 2026Led | $290 MOther Equity | |
Korsana Biosciences | Feb 2026Participated | $150 MSeries A | |
Mirador Therapeutics | Jan 2026Participated | $250 MSeries B | |
Jade Biosciences | Oct 2024Participated | $95 MOther Equity | |
Candid Therapeutics | Sep 2024Led | $370 MOther Equity | |
Jade Biosciences | Aug 2024Led | $80 MOther Equity | |
Bicycle Therapeutics | May 2024Participated | $555 MOther Equity | |
Zenas BioPharma | May 2024Participated | $200 MSeries C | |
Mirador Therapeutics | Mar 2024Participated | $400 MOther Equity | |
Bicara Therapeutics | Dec 2023Participated | $165 MSeries C | |
Zenas BioPharma | Nov 2022Participated | $118 MSeries B |
16 Items
16
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 2 | 1 |
| Series B | 0 | 3 |
| Series C+ | 0 | 2 |
| Other Equity | 4 | 4 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jul '20 | 1 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 2 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 1 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 1 |
| Apr '24 | 0 |
| May '24 | 2 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 1 |
| Sep '24 | 1 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 1 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 1 |
| Jun '26 | 0 |
| Jul '26 | 1 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 16 |
| Space & Frontier Tech | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 0 |
| $25M-$50M | 0 |
| $50M-$100M | 3 |
| $100M-$250M | 8 |
| $250M-$500M | 4 |
| $500M-$1B | 1 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 15 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Venrock | 11 |
| RTW Investments | 6 |
| Deep Track Capital | 5 |
| Logos Capital | 5 |
| TCGX | 5 |
| Wellington Management | 5 |
| Boxer Capital | 4 |
| Commodore Capital | 4 |
| Fidelity Management & Research Company | 4 |
| Janus Henderson Investors | 4 |
| OrbiMed | 4 |
| Perceptive Advisors | 4 |
| Vivo Capital | 4 |
| Braidwell | 3 |
| Driehaus Capital Management | 3 |
| Farallon Capital Management | 3 |
| Franklin Templeton | 3 |
| RA Capital Management | 3 |
| Agent Capital | 2 |
| ARCH Venture Partners | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 6 | 38% |
| Participating | 10 | 63% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 2 | 33% |
| Co-led | 4 | 67% |
Team
Michelle Pernice
Senior Vice President, Regulatory Affairs
Peter Harwin
Co-Founder and Managing Member